Skip to content

Clinical Research Dynamics

Response phase IV study

Sponsored by Genentech, Inc., the objective of this study is to assess the long term safety of Raptiva in patients with maderate to severe plaque psoriasis by evaluating patients on Raptiva as well as other biologics. In addition, it intends to associate patient outcomes with psoriasis treatment.